The primary objective of this study is to evaluate the effects of two different doses of
ANS-6637, 200 mg (given as 2 x 100 mg tablet) and 600 mg (given as 2 x 300 mg tablet) once a
day, and matched placebo, on alcohol cue-elicited alcohol craving during a human laboratory
paradigm after 1 week of daily dosing among subjects with moderate to severe alcohol use
disorder (AUD) as confirmed by the Diagnostic and Statistical Manual of Mental Disorders -
Fifth Edition (DSM-5™).
Phase:
Phase 2
Details
Lead Sponsor:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)